LSTA FY2025 EPS Decreased by Brookline Capital Management

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Brookline Capital Management dropped their FY2025 earnings per share (EPS) estimates for Lisata Therapeutics in a research report issued to clients and investors on Wednesday, January 21st. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($2.46) for the year, down from their previous forecast of ($2.09). Brookline Capital Management has a “Hold” rating on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share.

LSTA has been the subject of a number of other research reports. Zacks Research lowered shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Thursday. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $23.50.

Lisata Therapeutics Trading Up 1.2%

NASDAQ:LSTA opened at $4.11 on Friday. The firm has a market cap of $36.25 million, a P/E ratio of -1.93 and a beta of 1.11. Lisata Therapeutics has a 12 month low of $1.81 and a 12 month high of $4.17. The stock has a 50 day moving average of $2.15 and a two-hundred day moving average of $2.36.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Cerity Partners LLC acquired a new position in Lisata Therapeutics during the second quarter worth $32,000. Ground Swell Capital LLC acquired a new position in Lisata Therapeutics during the third quarter worth about $62,000. Finally, CIBC Bancorp USA Inc. purchased a new position in Lisata Therapeutics in the third quarter valued at about $37,000. 8.94% of the stock is currently owned by institutional investors and hedge funds.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.